Table 2.

Main outcomes of the efficient scenarios

Scenario	Scenario characteristicsa	Detected cancers at an early stage (I/II), %	Reduction in lung cancer mortality, %	Lung cancer deaths averted	Discounted life years gained	Interval cancer cases	Overdiagnosed cases	Overdiagnosis, %	Discounted total cost, million euro	Discounted additional costs vs no screening, million euro	Cost per life years gained vs no screening (uniform discounting), euro	Discounted cost per lung cancer death averted vs no screening, euro	ICER vs the previous efficient scenario, euro
Efficient scenarios based on the cost per life year gained ratio
Scenario 65	55-75-40-10-NELSON-VDT300-none	67.31	9.95	14,373	133,222	23,057	6733	9.48	10,892	2232	16,754	155,287	16,754
Scenario 60	55-75-40-10-NELSON-VDT400-V300	71.35	12.38	17,889	164,864	19,854	17,892	9.69	11,516	2855	17,321	159,625	19,707
Scenario 41	50-75-15-9-NELSON-VDT400-V300	72.39	11.90	37,075	362,039	43,331	32,183	17.78	29,456	7556	20,870	203,792	23,804
Efficient scenarios based on the cost per averted lung cancer death ratio
Scenario 65	55-75-40-10-NELSON-VDT300-none	67.31	9.95	14,373	133,222	23,057	6733	9.48	10,892	2232	16,754	155,287	155,287
Scenario 64	55-75-40-10-NELSON-VDT400-none	67.95	10.65	15,395	140,490	21,367	9184	11.73	11,057	2397	17,059	155,675	161,124
Scenario 60	55-75-40-10-NELSON-VDT400-V300	71.35	12.38	17,889	164,864	19,854	17,892	19.69	11,516	2855	17,321	159,625	184,009
Scenario 22	55-80-30-15-NELSON-VDT400-V300	70.95	12.80	29,165	260,807	32,071	33,473	21.76	18,846	5296	20,307	181,597	216,454
Scenario 41	50-75-15-9-NELSON-VDT400-V300	72.39	11.90	37,075	362,039	43,331	32,183	17.78	29,456	7556	20,870	203,792	285,630

^aScenarios are named ranging these values as follows: ”population selection criteria-nodule management protocol-threshold values for growth rate and nodule size”